Email bulletins

Archive

December 2016

  • Experimental treatments for hepatitis B
  • 8-week sofosbuvir/ledipasvir treatment course
  • DAA treatment in HIV/HCV co-infection
  • Adherence
  • Use of generic drugs for treatment of hepatitis C
  • Prequalified hepatitis C rapid test
  • Is this your copy of the infohep news bulletin?

November 2016

  • News from the 2016 AASLD Liver Meeting
  • New pangenotypic combinations
  • Hepatitis C genotype 3
  • Real world treatment performance matches the best clinical trial results
  • Treatment scale-up and the continuum of care
  • Liver cancer in people treated with direct-acting antivirals
  • Hepatitis B treatment
  • Generic hepatitis C drugs
  • Is this your copy of the infohep news bulletin?

October 2016

  • Over one million people treated for hepatitis C in low- and middle-income countries
  • FDA hepatitis B reactivation warning, and hepatitis B testing for people taking hepatitis C treatment
  • Hepatitis B elimination
  • European action plan for the health sector response to viral hepatitis
  • Reinfection risk
  • Mortality risk after SVR in Scotland
  • Shortening treatment
  • Access to treatment
  • Next month: news coverage of The Liver Meeting 2016
  • Is this your copy of the infohep news bulletin?

September 2016

  • New European guidelines for treatment of hepatitis C
  • HCV treatment for people who inject drugs
  • Alcohol and liver damage in people with hepatitis C
  • Reduced fatigue after hepatitis C cure
  • HCV vaccine
  • Access to sofosbuvir in Ukraine
  • International Viral Hepatitis Elimination Meeting 2016
  • Is this your copy of the infohep news bulletin?

August 2016

  • Hep-CORE study highlights gaps in European responses to viral hepatitis
  • Zepatier receives EU marketing approval
  • Risk factors for fibrosis progression
  • Statins and progression of fibrosis in people with HIV/HCV co-infection
  • Hepatitis B monitoring
  • Is this your copy of the infohep news bulletin?

July 2016

  • World Hepatitis Day: the launch of the NOhep movement
  • Sofosbuvir/velpatasvir (Epclusa) approval in European Union and United States
  • Viekirax treatment course for genotype 4 reduced in European Union
  • US treatment guidelines updated
  • Viral hepatitis worldwide
  • Diabetes, cirrhosis and liver cancer
  • Portal hypertension
  • Is this your copy of the infohep news bulletin?

June 2016

  • Access to hepatitis C treatment: France, Ireland and India
  • Hepatitis C treatment rationing
  • Global targets for the elimination of viral hepatitis
  • Making hepatitis C diagnosis easier
  • Is this your copy of the infohep news bulletin?

May 2016

  • Governments commit to eliminating viral hepatitis by 2030 at World Health Assembly
  • Two new DAA combinations set for approval in the European Union
  • Hepatitis B treatment
  • Hepatitis C burden of disease
  • Access to hepatitis C treatment
  • HIV and hepatitis C
  • Experimental treatment for cirrhosis
  • Head and neck cancers
  • The 5th International Symposium on Hepatitis Care in Substance Users
  • Is this your copy of the infohep news bulletin?

April 2016

  • News from the 2016 International Liver Congress
  • Infohep webinar recording
  • Generic drugs for hepatitis C treatment
  • New generic combination to be tested in clinical trials
  • NOhep campaign
  • Hepatitis C treatment highly effective in real-world settings
  • Hepatitis C treatment in advanced liver disease
  • Hepatitis C treatment for people whose first DAA regimen failed
  • Hepatitis C genotype 3 treatment
  • Reinfection and treatment in acute infection
  • Pangenotypic treatment in people with HIV/HCV co-infection
  • Is this your copy of the infohep news bulletin?

March 2016

  • WHO guidelines update
  • Counterfeit Harvoni in Europe
  • Hepatitis B prevalence
  • HIV and HCV co-infection
  • Treatment of acute HCV infection
  • Genotype 4
  • HCV and lymphoma
  • Screening for hepatitis C
  • Upcoming event at ILC 2016: Transforming HCV Care Together
  • Is this your copy of the infohep news bulletin?

February 2016

  • Daklinza label expanded in Europe
  • Cholesterol and liver damage in women with hepatitis C
  • Cryoglobulinemia and direct-acting antivirals
  • CDC warning on dialysis
  • Drug pricing controversy builds in the United States
  • Online treatment access data collection
  • Improving referral from primary care
  • Anti-microRNAs: a new experimental treatment for hepatitis C
  • World Hepatitis Alliance Webinars
  • Is this your copy of the infohep news bulletin?

January 2016

  • Cardiovascular disease and hepatitis C
  • Parkinson’s disease
  • Australia hepatitis C treatment funding
  • Hepatitis testing contest
  • New Merck combination Zepatier approved for hepatitis C treatment in the United States
  • New hepatitis C drugs in development
  • Hepatitis B treatment
  • Is this your copy of the infohep news bulletin?